A new study has unveiled that Zepbound, which contains the active ingredient tirzepatide, leads to greater weight loss compared to Wegovy, which contains semaglutide. This research conducted by Eli Lilly found that after 72 weeks of treatment, participants using Zepbound lost 20% of their body weight, nearly 50 pounds on average, while those on Wegovy lost just under 14%, translating to about 33 pounds.
The clinical trial included 751 individuals suffering from obesity or related medical conditions, demonstrating significant results for both medications. This data follows a recent study indicating that another drug, Mounjaro (also containing tirzepatide), is more effective than Ozempic, which also uses semaglutide.
Both Zepbound and Wegovy are FDA-approved for weight loss, functioning by enhancing insulin production from the pancreas and slowing gastric movement, which curtails appetite and promotes weight loss. Dr. Louis Aronne, involved in the study, suggests that the effectiveness of tirzepatide stems from its ability to target dual hormones, compared to semaglutide which targets just one. This dual-action approach appears to facilitate greater weight loss results.
While Zepbound’s success may be more pronounced in some patients, the decision on which medication to use should be personalized, as individual needs and responses can vary. Eli Lilly will also sell Zepbound directly to consumers without insurance coverage, reflecting a shift towards more accessible obesity treatment options.
Furthermore, maintaining a weight-loss regimen with either medication necessitates lifestyle changes including cardio and strength training, and adopting a diet rich in proteins while minimizing processed foods and added sugars. Commonly reported side effects include nausea and constipation, with more serious risks necessitating discussions with healthcare providers before starting any new medication.
Source: AOL.com
